leisure time -WSS

leisure time

author：leisure time 2025-09-30 08:52:21 - browse：58565

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Wikipedia

WSS

Appeals court upholds limits to abortion pill

Why Novartis is going to walk from its acquisition of MorphoSys

Cano Health’s bankruptcy is a warning for Medicare Advantage

Appeals court upholds limits to abortion pill

Australia’s approach to dialysis celebrates life

Cano Health’s bankruptcy is a warning for Medicare Advantage

Wikipedia

leisure time

explore

Alkermes shareholders re

Problems with a popular proposal to regulate AI in health care

George Santos makes 1st court appearance after pleading not guilty to 13 counts

In science, is the line between industry and academia shifting?

23andMe had bad news about my health. I wish a person had delivered it

FDA panel gives mixed vote on blood pressure devices

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

The cancer drug shortage isn’t new — and neither are the solutions

What’s missing from the debate over nursing home staff minimums

focus

Gene therapy for Afghan refugees’ infant will be fully covered

Diversity in medical illustrations gets boost from Chidiebere Ibe

Why Novartis is going to walk from its acquisition of MorphoSys

Cano Health’s bankruptcy is a warning for Medicare Advantage

Top private equity targets in 2023: cardiology, clinical trials, lasers

340B reform proposal comes out of Senate working group

Wikipedia

focus

knowledge

explore